-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Changchun Hi-Tech, the once 100 billion pharmaceutical big white horse, has fallen by the limit for three consecutive days
.
From January 19th to 20th, Changchun Hi-Tech's stock price fell by the limit for two consecutive days.
The new stock price was reported at 204.
84 yuan per share, and the new total market value was 82.
9 billion yuan
.
In addition, at 9:26 on January 21, Changchun Hi-Tech opened at a limit of 184.
36 yuan, and currently has 85,437 orders, equivalent to 1.
575 billion yuan
.
Up to now, the transaction has been 127 million yuan, and the turnover rate is 0.
19%
.
As of January 20, in the past month, Changchun Hi-Tech's stock price has fallen by nearly 30%
.
Judging from the public information, Changchun High-tech's lower limit may be related to the notice of "Guangdong Alliance Diclofenac and Other Drugs Concentrated Procurement Documents" issued by the Guangdong Provincial Drug Trading Center on January 19
.
In the relevant documents, a number of recombinant human growth hormone products are on the list, including the recombinant human growth hormone injection and recombinant human growth hormone for injection of Changchun High-tech subsidiary Changchun Jinsai Pharmaceutical Co.
,
Ltd.
Analysts pointed out that due to the general decline in drug prices brought about by centralized procurement, the capital market was worried that it would affect the performance of listed companies, and stock prices fluctuated greatly
.
According to public information, growth hormone is mainly divided into three dosage forms: powder injection, water injection, and long-acting
.
The industry believes that from the perspective of the previous situation, the price limit of water needles is relatively low, with a drop of 70%, far exceeding the bottom line of market expectations
.
The main business income of Changchun High-tech is concentrated in Shuijing, so the valuation model of the past stock price is invalid, and it faces the result of re-pricing
.
Regarding the fluctuation of stock prices, on January 20, Changchun Hi-Tech stated on the interactive platform that the bidding process has not yet officially started for this centralized drug procurement, and the specific impact will also depend on the actual participation in the bidding, the results of the selection, and the selection.
Prices, etc.
, follow-up events and the degree of impact on the company are still uncertain.
At present, there is no expectation that it will have a serious impact on the company's operating performance.
The company will actively pay attention to the follow-up progress, carefully study the relevant documents and regulations, and formulate a reasonable implementation plan
.
According to the data, Changchun Hi-Tech's main business is the research and development, production and sales of biopharmaceuticals and proprietary Chinese medicines, supplemented by real estate development, property management and services, and is the leader in growth hormones in China
.
In the past five years, the company's revenue and net profit attributable to the parent have maintained double-digit growth
.
Among them, in the first three quarters of 2021, the company's operating income increased by nearly 29% year-on-year to 8.
239 billion yuan; the net profit attributable to the parent company increased by 39% year-on-year to 3.
147 billion yuan
.
In terms of performance, Changchun High-tech is more dependent on Jinsai Pharmaceutical, a core subsidiary engaged in the research and development of various recombinant human growth hormones
.
The data shows that in 2020, Jinsai Pharmaceutical achieved revenue of 5.
803 billion yuan, contributing 67.
66% of the revenue to Changchun Hi-tech; net profit was 2.
760 billion yuan, contributing 90.
58% of the net profit to Changchun Hi-tech
.
In the first three quarters of 2021, the subsidiary Jinsai Pharmaceutical achieved revenue of 6.
161 billion yuan, accounting for 74.
78% of Changchun Hi-tech's total revenue; realized a net profit of 3.
042 billion yuan, accounting for 92.
51% of Changchun Hi-tech's net profit
.
Some people pointed out that long before the pharmaceutical white horse stock Changchun High-tech fell by the limit, the pharmaceutical-themed fund fluctuated violently due to its net worth
.
According to data from Oriental Fortune Choice, as of January 19, the average increase in the net value of 197 pharmaceutical manufacturing themed funds in the past year was -14.
22%, and the average increase in the net value of active stock funds in the same period was -1.
01%.
The average increase in the net value of the fund range is 0.
55%
.
.
From January 19th to 20th, Changchun Hi-Tech's stock price fell by the limit for two consecutive days.
The new stock price was reported at 204.
84 yuan per share, and the new total market value was 82.
9 billion yuan
.
In addition, at 9:26 on January 21, Changchun Hi-Tech opened at a limit of 184.
36 yuan, and currently has 85,437 orders, equivalent to 1.
575 billion yuan
.
Up to now, the transaction has been 127 million yuan, and the turnover rate is 0.
19%
.
As of January 20, in the past month, Changchun Hi-Tech's stock price has fallen by nearly 30%
.
Judging from the public information, Changchun High-tech's lower limit may be related to the notice of "Guangdong Alliance Diclofenac and Other Drugs Concentrated Procurement Documents" issued by the Guangdong Provincial Drug Trading Center on January 19
.
In the relevant documents, a number of recombinant human growth hormone products are on the list, including the recombinant human growth hormone injection and recombinant human growth hormone for injection of Changchun High-tech subsidiary Changchun Jinsai Pharmaceutical Co.
,
Ltd.
Analysts pointed out that due to the general decline in drug prices brought about by centralized procurement, the capital market was worried that it would affect the performance of listed companies, and stock prices fluctuated greatly
.
According to public information, growth hormone is mainly divided into three dosage forms: powder injection, water injection, and long-acting
.
The industry believes that from the perspective of the previous situation, the price limit of water needles is relatively low, with a drop of 70%, far exceeding the bottom line of market expectations
.
The main business income of Changchun High-tech is concentrated in Shuijing, so the valuation model of the past stock price is invalid, and it faces the result of re-pricing
.
Regarding the fluctuation of stock prices, on January 20, Changchun Hi-Tech stated on the interactive platform that the bidding process has not yet officially started for this centralized drug procurement, and the specific impact will also depend on the actual participation in the bidding, the results of the selection, and the selection.
Prices, etc.
, follow-up events and the degree of impact on the company are still uncertain.
At present, there is no expectation that it will have a serious impact on the company's operating performance.
The company will actively pay attention to the follow-up progress, carefully study the relevant documents and regulations, and formulate a reasonable implementation plan
.
According to the data, Changchun Hi-Tech's main business is the research and development, production and sales of biopharmaceuticals and proprietary Chinese medicines, supplemented by real estate development, property management and services, and is the leader in growth hormones in China
.
In the past five years, the company's revenue and net profit attributable to the parent have maintained double-digit growth
.
Among them, in the first three quarters of 2021, the company's operating income increased by nearly 29% year-on-year to 8.
239 billion yuan; the net profit attributable to the parent company increased by 39% year-on-year to 3.
147 billion yuan
.
In terms of performance, Changchun High-tech is more dependent on Jinsai Pharmaceutical, a core subsidiary engaged in the research and development of various recombinant human growth hormones
.
The data shows that in 2020, Jinsai Pharmaceutical achieved revenue of 5.
803 billion yuan, contributing 67.
66% of the revenue to Changchun Hi-tech; net profit was 2.
760 billion yuan, contributing 90.
58% of the net profit to Changchun Hi-tech
.
In the first three quarters of 2021, the subsidiary Jinsai Pharmaceutical achieved revenue of 6.
161 billion yuan, accounting for 74.
78% of Changchun Hi-tech's total revenue; realized a net profit of 3.
042 billion yuan, accounting for 92.
51% of Changchun Hi-tech's net profit
.
Some people pointed out that long before the pharmaceutical white horse stock Changchun High-tech fell by the limit, the pharmaceutical-themed fund fluctuated violently due to its net worth
.
According to data from Oriental Fortune Choice, as of January 19, the average increase in the net value of 197 pharmaceutical manufacturing themed funds in the past year was -14.
22%, and the average increase in the net value of active stock funds in the same period was -1.
01%.
The average increase in the net value of the fund range is 0.
55%
.
